Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multiple Dark Antigens program - ovarian
- Development stage
- Preclinical
- Lead developer
- Enara Bio
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
The Multiple Dark Antigens program for ovarian cancer is a therapeutic vaccine being developed by Enara Bio. This immunotherapy utilizes the company's proprietary Dark Antigen® discovery platform, which identifies novel tumor-specific targets derived from the genomic 'dark matter'—regions of the genome traditionally considered non-coding, such as introns and retrotransposons. These antigens are aberrantly expressed in ovarian cancer cells but remain silenced in healthy tissues, providing a high degree of tumor specificity. The vaccine is designed to prime and activate the patient's immune system, specifically T-cells, to recognize and eliminate cancer cells expressing these dark antigens, potentially overcoming the limitations of conventional shared tumor antigens.
- Other names
- Enara Bio ovarian cancer vaccineMultiple Dark Antigens therapeutic vaccine - ovarian cancer
02
Targets
Multiple tumor-specific Dark Antigen peptide-HLA complexes
Beyond the preview
Go deeper on Multiple Dark Antigens program - ovarian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multiple Dark Antigens program - ovarian.